340 related articles for article (PubMed ID: 16439177)
1. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients.
Rolston KV; Yadegarynia D; Kontoyiannis DP; Raad II; Ho DH
Int J Infect Dis; 2006 May; 10(3):223-30. PubMed ID: 16439177
[TBL] [Abstract][Full Text] [Related]
2. Microbial spectrum and antibiotic susceptibility profile of gram-positive aerobic bacteria isolated from cancer patients.
Ashour HM; el-Sharif A
J Clin Oncol; 2007 Dec; 25(36):5763-9. PubMed ID: 18089873
[TBL] [Abstract][Full Text] [Related]
3. Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Reddy AK; Garg P; Alam MR; Gopinathan U; Sharma S; Krishnaiah S
Eye (Lond); 2010 Jan; 24(1):170-4. PubMed ID: 19229279
[TBL] [Abstract][Full Text] [Related]
4. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
[TBL] [Abstract][Full Text] [Related]
5. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
Ismaeel NA; Tayeb OS
Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
[TBL] [Abstract][Full Text] [Related]
7. In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients.
Rolston KV; Vaziri I; Frisbee-Hume S; Streeter H; LeBlanc B
Chemotherapy; 2004 Nov; 50(5):214-20. PubMed ID: 15523180
[TBL] [Abstract][Full Text] [Related]
8. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients.
Gudiol C; Bodro M; Simonetti A; Tubau F; González-Barca E; Cisnal M; Domingo-Domenech E; Jiménez L; Carratalà J
Clin Microbiol Infect; 2013 May; 19(5):474-9. PubMed ID: 22524597
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
Rotstein C; Amsterdam D; Beam TR; Mandell LA; Gorzynski EA
Diagn Microbiol Infect Dis; 1993 Jul; 17(1):85-91. PubMed ID: 8395375
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies.
Timmers GJ; Dijstelbloem Y; Simoons-Smit AM; van Winkelhoff AJ; Touw DJ; Vandenbroucke-Grauls CM; Huijgens PC
Bone Marrow Transplant; 2004 Apr; 33(8):847-53. PubMed ID: 14755314
[TBL] [Abstract][Full Text] [Related]
11. [In vitro evaluation of lomefloxacin].
Dette GA; Knothe H
Arzneimittelforschung; 1989 Aug; 39(8):832-5. PubMed ID: 2818672
[TBL] [Abstract][Full Text] [Related]
12. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
Beskid G; Prosser BL
Am J Med; 1993 Mar; 94(3A):2S-8S. PubMed ID: 8383919
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
Barry AL; Fuchs PC; Brown SD
Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655
[TBL] [Abstract][Full Text] [Related]
14. Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones.
Rolston KV; Kontoyiannis DP; Yadegarynia D; Raad II
Diagn Microbiol Infect Dis; 2005 Mar; 51(3):215-8. PubMed ID: 15766609
[TBL] [Abstract][Full Text] [Related]
15. Gram-negative organisms predominate in Hickman line-related infections in non-neutropenic patients with hematological malignancies.
Chee L; Brown M; Sasadeusz J; MacGregor L; Grigg AP
J Infect; 2008 Apr; 56(4):227-33. PubMed ID: 18342947
[TBL] [Abstract][Full Text] [Related]
16. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison.
Duggirala A; Joseph J; Sharma S; Nutheti R; Garg P; Das T
Indian J Ophthalmol; 2007; 55(1):15-9. PubMed ID: 17189881
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria.
Moros M; Coll R; Esteve M; Parés J; Xicota MA
Chemioterapia; 1987 Jun; 6(2 Suppl):149-51. PubMed ID: 3509373
[No Abstract] [Full Text] [Related]
18. Overview of the fluoroquinolone antibiotics.
Just PM
Pharmacotherapy; 1993; 13(2 Pt 2):4S-17S. PubMed ID: 8386356
[TBL] [Abstract][Full Text] [Related]
19. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
Almer LS; Hoffrage JB; Keller EL; Flamm RK; Shortridge VD
Antimicrob Agents Chemother; 2004 Jul; 48(7):2771-7. PubMed ID: 15215148
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Blondeau JM; Laskowski R; Bjarnason J; Stewart C
Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
